Clinical features, treatment, and outcome of nivolumab induced cholangitis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical features, treatment, and outcome of nivolumab induced cholangitis

Published:2024-09-08 Issue: Volume: Page:1-16
ISSN:0892-3973
Container-title:Immunopharmacology and Immunotoxicology
language:en
Short-container-title:Immunopharmacology and Immunotoxicology

Author:

He Yang¹²,Fan Zhiqiang¹,Sun Wei³,Ouyang Linqi¹,Wang Chunjiang³

Affiliation:

1. Department of pharmacy, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan,410007, China.

2. College of pharmacy, Changsha Medical University, Changsha, Hunan, 410219, China.

3. Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/08923973.2024.2402338

Reference30 articles.

1. The blockade of immune checkpoints in cancer immunotherapy

2. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

3. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

4. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial

5. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP